Hangzhou Bai Cheng Pharmaceutical Technology Co., Ltd. announces its wholly-owned subsidiary, Zhejiang Semo Pharmaceutical Co., Ltd., has been selected in the 12th batch of national centralized drug procurement for its Sitagliptin and Metformin Hydrochloride Extended-Release Tablets. This selection is expected to positively impact future sales and market expansion.
Summary generated by AI · Always verify with source document
Securities Code: 301096
Securities Abbreviation: Bai Cheng Pharmaceutical
Announcement No.: 2026-037
Hangzhou Bai Cheng Pharmaceutical Technology Co., Ltd.
Announcement on Wholly-Owned Subsidiary's Selection in National Centralized Drug Procurement
The Company and the entire Board of Directors guarantee that the content of information disclosure is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.